NTT DATA Group Corporation (TYO:9613)
Japan · Delayed Price · Currency is JPY 3,958.00
-2.00 (-0.05%)
Aug 8, 2025, 3:30 PM JST
Inozyme Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Revenue | 4,630,992 | 4,638,721 | 4,367,387 | 3,490,182 | 2,551,906 | 2,318,658 | Upgrade |
Revenue Growth (YoY) | 3.73% | 6.21% | 25.13% | 36.77% | 10.06% | 2.29% | Upgrade |
Cost of Revenue | 3,328,500 | 3,351,333 | 3,172,421 | 2,567,948 | 1,875,904 | 1,734,083 | Upgrade |
Gross Profit | 1,302,492 | 1,287,388 | 1,194,966 | 922,234 | 676,002 | 584,575 | Upgrade |
Selling, General & Admin | 978,486 | 963,525 | 885,416 | 663,124 | 463,411 | 445,402 | Upgrade |
Operating Expenses | 978,486 | 963,527 | 885,417 | 664,995 | 463,411 | 446,370 | Upgrade |
Operating Income | 324,006 | 323,861 | 309,549 | 257,239 | 212,591 | 138,205 | Upgrade |
Interest Expense | -105,445 | -102,217 | -80,054 | -29,496 | -5,688 | -6,383 | Upgrade |
Interest & Investment Income | 24,688 | 22,754 | 21,903 | 11,941 | 4,197 | 4,819 | Upgrade |
Earnings From Equity Investments | 3,709 | 1,395 | 304 | 405 | -205 | -6,299 | Upgrade |
Currency Exchange Gain (Loss) | - | -1,772 | -3,730 | -1,149 | 2,728 | -1,520 | Upgrade |
Other Non Operating Income (Expenses) | -2 | 4,985 | 630 | 3,861 | 2,226 | 1,629 | Upgrade |
EBT Excluding Unusual Items | 246,956 | 249,006 | 248,602 | 242,801 | 215,849 | 130,451 | Upgrade |
Pretax Income | 245,974 | 249,006 | 248,602 | 242,801 | 215,849 | 130,451 | Upgrade |
Income Tax Expense | 106,562 | 109,746 | 103,062 | 75,929 | 65,747 | 48,751 | Upgrade |
Earnings From Continuing Operations | 139,412 | 139,260 | 145,540 | 166,872 | 150,102 | 81,700 | Upgrade |
Minority Interest in Earnings | 2,882 | 3,194 | -11,671 | -16,910 | -7,123 | -4,857 | Upgrade |
Net Income | 142,294 | 142,454 | 133,869 | 149,962 | 142,979 | 76,843 | Upgrade |
Net Income to Common | 142,294 | 142,454 | 133,869 | 149,962 | 142,979 | 76,843 | Upgrade |
Net Income Growth | 11.64% | 6.41% | -10.73% | 4.88% | 86.07% | 2.26% | Upgrade |
Shares Outstanding (Basic) | 1,402 | 1,402 | 1,402 | 1,402 | 1,402 | 1,402 | Upgrade |
Shares Outstanding (Diluted) | 1,402 | 1,402 | 1,402 | 1,402 | 1,402 | 1,402 | Upgrade |
Shares Change (YoY) | 0.01% | 0.01% | -0.01% | -0.02% | -0.01% | - | Upgrade |
EPS (Basic) | 101.49 | 101.60 | 95.48 | 106.95 | 101.95 | 54.79 | Upgrade |
EPS (Diluted) | 101.49 | 101.60 | 95.48 | 106.95 | 101.95 | 54.79 | Upgrade |
EPS Growth | 11.64% | 6.41% | -10.72% | 4.91% | 86.08% | 2.26% | Upgrade |
Free Cash Flow | -214,159 | -292,888 | -155,684 | -16,193 | 135,410 | 189,378 | Upgrade |
Free Cash Flow Per Share | -152.74 | -208.90 | -111.04 | -11.55 | 96.55 | 135.03 | Upgrade |
Dividend Per Share | 25.000 | 25.000 | 23.000 | 22.000 | 19.000 | 18.000 | Upgrade |
Dividend Growth | 8.70% | 8.70% | 4.54% | 15.79% | 5.56% | - | Upgrade |
Gross Margin | 28.13% | 27.75% | 27.36% | 26.42% | 26.49% | 25.21% | Upgrade |
Operating Margin | 7.00% | 6.98% | 7.09% | 7.37% | 8.33% | 5.96% | Upgrade |
Profit Margin | 3.07% | 3.07% | 3.06% | 4.30% | 5.60% | 3.31% | Upgrade |
Free Cash Flow Margin | -4.62% | -6.31% | -3.56% | -0.46% | 5.31% | 8.17% | Upgrade |
EBITDA | 689,076 | 688,022 | 651,090 | 530,291 | 432,530 | 352,529 | Upgrade |
EBITDA Margin | 14.88% | 14.83% | 14.91% | 15.19% | 16.95% | 15.20% | Upgrade |
D&A For EBITDA | 365,070 | 364,161 | 341,541 | 273,052 | 219,939 | 214,324 | Upgrade |
EBIT | 324,006 | 323,861 | 309,549 | 257,239 | 212,591 | 138,205 | Upgrade |
EBIT Margin | 7.00% | 6.98% | 7.09% | 7.37% | 8.33% | 5.96% | Upgrade |
Effective Tax Rate | 43.32% | 44.07% | 41.46% | 31.27% | 30.46% | 37.37% | Upgrade |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.